A Phase 4 interventional study of Ustekinumab 90 mg SC q8w and Ustekinumab 90 mg SC q12w in Crohn Disease (CD) and Ulcerative Colitis (UC), sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing ustekinumab in Crohn Disease — 3 open to participants now, 5 under way, 2 of them phase 3. Ustekinumab · Crohn Disease.
Among the 21 studies testing ustekinumab in Crohn Disease, this one is the 12th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 21st registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →3 of the 21 studies testing ustekinumab in Crohn Disease are open now, in 3 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–70
By country, each count listing its studies:
Ustekinumab: first FDA approval 2009 (STELARA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 9 · Phase 4 5
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 115 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 131 across the 21 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
McGill University Health Centre/Research Institute of the McGill University Health Centre has 4 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
3 of the studies testing ustekinumab in Crohn Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT06520397Sixth Affiliated Hospital, Sun Yat-sen UniversityEfficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease | 2026-12-31 |
| NCT07303686McGill University Health Centre/Research Institute of the McGill University Health CentreDe-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis | 2027-04-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing ustekinumab in Crohn Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST).
The main question it aims to answer is:
Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission.
Participants will:
Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.
Participation in this research study will last 12 months and will include 4-6 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Ustekinumab 90 mg SC q8w
Biological: Ustekinumab 90 mg SC q12w
Sub-group switching from Q4w to Q8w
Sub-group switching from Q8w to Q12w
Loss of clinical remission
Proportion of patients experiencing loss of remission
Time frame: From treatment switch to end of participation (12 months)
Time-to-loss of Remission
Time frame: From treatment switch to end of participation (12 months)
Change from Baseline in the C-reactive protein (CRP) level at loss of remission.
To define if CRP level is a predictor of loss of remission.
Time frame: 12 months
Change from Baseline in the calprotectin level at loss of remission.
To define if calprotectin level is a predictor of loss of remission.
Time frame: 12 months
Disease duration before loss of remission.
Define if disease duration is a predictor of loss of remission.
Time frame: Up to 50 years.
Change in drug concentration before loss of remission.
Define if drug concentration in blood is a predictor of loss of remission.
Time frame: 12 months
Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.
Of 54 non-industry phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 71. This study's planned 18 months is below that.
Counting every sponsor, half of 70 studies reached it within 56 months; a quarter within 35 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ustekinumab
McGill University Health Centre/Research Institute of the McGill University Health Centre →